Tolerance of Inactivated SARS-CoV-2 Vaccine for People Living with HIV: A Real-World Evidence Analysis from a Retrospective Cohort Study.

IF 3.1 4区医学 Q1 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH

Journal of Epidemiology and Global Health Pub Date : 2025-08-14 DOI:10.1007/s44197-025-00452-4

Qian He, Tao Zhou, Ying Feng, Yuefei Li, Zhen Ni, Ning Zhang, Jing Chen, Mingjian Ni, Shi Zhao, Kai Wang

{"title":"Tolerance of Inactivated SARS-CoV-2 Vaccine for People Living with HIV: A Real-World Evidence Analysis from a Retrospective Cohort Study.","authors":"Qian He, Tao Zhou, Ying Feng, Yuefei Li, Zhen Ni, Ning Zhang, Jing Chen, Mingjian Ni, Shi Zhao, Kai Wang","doi":"10.1007/s44197-025-00452-4","DOIUrl":null,"url":null,"abstract":"Background: The tolerance of inactivated SARS-CoV-2 vaccines in people living with HIV (PLWH) remains unclear. We aimed to evaluate the tolerance of inactivated SARS-CoV-2 vaccines in PLWH.Methods: This retrospective cohort study recruited 3327 PLWH for questionnaires and laboratory testing. Subjects were screened to ensure they were receiving antiretroviral therapy for PLWH without SARS-CoV-2 infection. Poisson regression analyses were conducted to assess the association between vaccination and HIV viral rebound, estimating absolute risk difference and relative risk (RR).Results: A total of 724 PLWH without SARS-CoV-2 infection participated in this study. No significant increase in HIV viral rebound risk was observed after vaccination in the 1/2-dose, 3-dose, and 4-dose groups compared to the 0-dose group. The RRs for the 1/2-dose, 3-dose, and 4-dose groups were 1.22 (95% confidence interval [CI]: 0.55, 2.72), 0.90 (95% CI: 0.48, 1.69), and 1.01 (95% CI: 0.35, 2.89), respectively. Similar results were observed across subgroups. Post-vaccination adverse reactions were minimal, occurring in 2.16% of cases, mostly fatigue and muscle soreness.Conclusion: Our study suggests that inactivated SARS-CoV-2 vaccines do not adversely affect the risk of HIV viral rebound and were well-tolerated in PLWH.","PeriodicalId":15796,"journal":{"name":"Journal of Epidemiology and Global Health","volume":"15 1","pages":"106"},"PeriodicalIF":3.1000,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12354443/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Epidemiology and Global Health","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s44197-025-00452-4","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The tolerance of inactivated SARS-CoV-2 vaccines in people living with HIV (PLWH) remains unclear. We aimed to evaluate the tolerance of inactivated SARS-CoV-2 vaccines in PLWH.

Methods: This retrospective cohort study recruited 3327 PLWH for questionnaires and laboratory testing. Subjects were screened to ensure they were receiving antiretroviral therapy for PLWH without SARS-CoV-2 infection. Poisson regression analyses were conducted to assess the association between vaccination and HIV viral rebound, estimating absolute risk difference and relative risk (RR).

Results: A total of 724 PLWH without SARS-CoV-2 infection participated in this study. No significant increase in HIV viral rebound risk was observed after vaccination in the 1/2-dose, 3-dose, and 4-dose groups compared to the 0-dose group. The RRs for the 1/2-dose, 3-dose, and 4-dose groups were 1.22 (95% confidence interval [CI]: 0.55, 2.72), 0.90 (95% CI: 0.48, 1.69), and 1.01 (95% CI: 0.35, 2.89), respectively. Similar results were observed across subgroups. Post-vaccination adverse reactions were minimal, occurring in 2.16% of cases, mostly fatigue and muscle soreness.

Conclusion: Our study suggests that inactivated SARS-CoV-2 vaccines do not adversely affect the risk of HIV viral rebound and were well-tolerated in PLWH.

查看原文本刊更多论文

艾滋病毒感染者对灭活SARS-CoV-2疫苗的耐受性：来自回顾性队列研究的真实世界证据分析

背景：HIV感染者（PLWH）对SARS-CoV-2灭活疫苗的耐受性尚不清楚。我们的目的是评估PLWH患者对SARS-CoV-2灭活疫苗的耐受性。方法：采用回顾性队列研究方法，招募3327名PLWH进行问卷调查和实验室检测。对受试者进行筛选，以确保他们在没有SARS-CoV-2感染的情况下接受PLWH的抗逆转录病毒治疗。泊松回归分析评估疫苗接种与HIV病毒反弹之间的关系，估计绝对风险差异和相对风险（RR）。结果：共有724名未感染SARS-CoV-2的PLWH参与本研究。与0剂量组相比，接种1/2剂量、3剂量和4剂量组后HIV病毒反弹风险未见显著增加。1/2剂量、3剂量和4剂量组的相对危险度分别为1.22（95%可信区间[CI]: 0.55, 2.72）、0.90 （95% CI: 0.48, 1.69）和1.01 （95% CI: 0.35, 2.89）。在各个亚组中观察到类似的结果。疫苗接种后的不良反应最小，发生在2.16%的病例中，主要是疲劳和肌肉酸痛。结论：我们的研究表明，灭活的SARS-CoV-2疫苗不会对HIV病毒反弹的风险产生不利影响，并且在PLWH中耐受性良好。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Epidemiology and Global Health Medicine-Epidemiology

CiteScore

10.70

自引率

1.40%

发文量

审稿时长

19 weeks

期刊介绍： The Journal of Epidemiology and Global Health is an esteemed international publication, offering a platform for peer-reviewed articles that drive advancements in global epidemiology and international health. Our mission is to shape global health policy by showcasing cutting-edge scholarship and innovative strategies.